JP2007513059A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513059A5
JP2007513059A5 JP2006529497A JP2006529497A JP2007513059A5 JP 2007513059 A5 JP2007513059 A5 JP 2007513059A5 JP 2006529497 A JP2006529497 A JP 2006529497A JP 2006529497 A JP2006529497 A JP 2006529497A JP 2007513059 A5 JP2007513059 A5 JP 2007513059A5
Authority
JP
Japan
Prior art keywords
weeks
gastrin
pharmaceutical composition
composition according
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006529497A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513059A (ja
Filing date
Publication date
Priority claimed from PCT/US2003/016660 external-priority patent/WO2003100024A2/en
Application filed filed Critical
Priority claimed from PCT/CA2004/000769 external-priority patent/WO2004105780A2/en
Publication of JP2007513059A publication Critical patent/JP2007513059A/ja
Publication of JP2007513059A5 publication Critical patent/JP2007513059A5/ja
Pending legal-status Critical Current

Links

JP2006529497A 2003-05-27 2004-05-27 ガストリン化合物を含む組成物および糖尿病におけるそれらの使用 Pending JP2007513059A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2003/016660 WO2003100024A2 (en) 2002-05-24 2003-05-27 Treatment for diabetes
PCT/CA2004/000769 WO2004105780A2 (en) 2003-05-27 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes

Publications (2)

Publication Number Publication Date
JP2007513059A JP2007513059A (ja) 2007-05-24
JP2007513059A5 true JP2007513059A5 (https=) 2007-07-12

Family

ID=33488788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006529497A Pending JP2007513059A (ja) 2003-05-27 2004-05-27 ガストリン化合物を含む組成物および糖尿病におけるそれらの使用

Country Status (11)

Country Link
EP (1) EP1648495A2 (https=)
JP (1) JP2007513059A (https=)
CN (1) CN1829528A (https=)
AU (1) AU2004243541A1 (https=)
BR (1) BRPI0410710A (https=)
CA (1) CA2527186A1 (https=)
MX (1) MXPA05012605A (https=)
NO (1) NO20055582L (https=)
PL (1) PL379145A1 (https=)
RU (1) RU2005140518A (https=)
WO (1) WO2004105780A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156828A0 (en) 2001-01-12 2004-02-08 Waratah Pharmaceuticals Inc Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US7560425B2 (en) 2002-06-07 2009-07-14 Waratah Pharmaceuticals Inc. Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
US20090202494A1 (en) * 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
WO2008106779A1 (en) * 2007-03-02 2008-09-12 Waratah Pharmaceuticals Inc. Gastrin compound for diabetes treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
DE69431212T2 (de) * 1994-01-24 2003-04-10 The General Hospital Corp., Boston Behandlung von diabetes
IL156828A0 (en) * 2001-01-12 2004-02-08 Waratah Pharmaceuticals Inc Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
KR20050074492A (ko) * 2002-10-22 2005-07-18 와라타 파마수티컬즈, 인크. 당뇨병의 치료

Similar Documents

Publication Publication Date Title
US10335462B2 (en) Use of long-acting GLP-1 peptides
US20230414773A1 (en) Elp fusion proteins for controlled and sustained release
EP2324853B1 (en) Lixisenatide as add-on to metformin in the treatment of diabetes type 2
EP2329848B2 (en) Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes
JP2006506386A5 (https=)
WO2009048945A1 (en) Rapid mucosal gel or film insulin compositions
CN103167878A (zh) 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病
US20240366533A1 (en) Sublingual Epinephrine Tablets
US20250319163A1 (en) Treatment of type 2 diabetes mellitus
JP2007513059A5 (https=)
RU2005140518A (ru) Композиции и способы, включающие соединения гастрина
CA2666846C (en) Method of restoring the incretin effect
Chakraborti Exenatide: a new promising antidiabetic agent
Pitocco et al. Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents
Kang Current therapeutic agents and anesthetic considerations for diabetes mellitus
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
EP4090351B1 (en) Dosing regimen of glp-1
Chaurasia A 100 Years Journey of Insulin
Fredenrich et al. Dipeptidyl peptidase inhibitors: A new step towards normoglycemia
TW202529797A (zh) Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
Liebelt Newer antidotal therapies for pediatric poisonings
CN106924723B (zh) 经口腔黏膜给药的含人胰高血糖素样肽-1类似物的药物组合物
ES2724731T3 (es) Composición farmacéutica
Ahammad et al. Incretin-Based Antidiabetic Agents: A New Option for Type-2 Diabetes Mellitus
Plengvidhya Novel Therapeutic Approach of Type 2 Diabetes Mellitus